Pharmacogenomics Research Network (U01/U19) | Apply Online

Frequently Asked Questions (FAQs) - Pharmacogenomics Research Network (PGRN) (U01/U19)

What is the Pharmacogenomics Research Network (PGRN) (U01/U19) funding opportunity?

This NIH funding opportunity was designed to bring new and existing research groups into a coordinated national consortium focused on pharmacogenomics. It supports collaborative, interdisciplinary teams studying why individuals respond differently to medications, including differences in therapeutic benefit and risk of adverse drug reactions.

Which NIH institutes participated in this PGRN opportunity?

The opportunity was issued through the National Institutes of Health with participation from multiple institutes: NIGMS, NHLBI, NCI, NIDA, NIMH, and NICHD.

What is the main goal of the program?

The central goal is to support coordinated, collaborative research that explains variability in drug response and advances knowledge that can improve medication safety and effectiveness.

What kinds of research topics does the opportunity focus on?

The program targets high-priority challenges in medication safety and effectiveness, including genetic and genomic contributors to therapeutic response and adverse drug reactions, and aims to connect discovery to functional understanding and clinical relevance.

Does the program emphasize collaboration and teamwork?

Yes. A core expectation is that applicants assemble truly cross-disciplinary teams and participate as part of a coordinated national consortium, reflecting the networked nature of the Pharmacogenomics Research Network.

What does the program mean by a "full pipeline" from discovery to clinical relevance?

Applicants are expected to identify high-priority medication-related problems, use strong genetic/genomic approaches for gene discovery (including replication), determine the functional consequences of identified variants, and assess the clinical implications of genotyping for improving prescribing and reducing adverse events.

What methods or approaches are encouraged for gene discovery?

The opportunity encourages leveraging important sample collections and applying appropriate genetic and genomic methods for gene discovery, including both discovery and replication studies, to identify variation in key genes and biological pathways affecting drug response.

Is replication of findings explicitly encouraged?

Yes. The goals include conducting both discovery and replication studies as part of identifying genetic variants that influence drug response.

Does the opportunity include functional studies of genetic variants?

Yes. Beyond identifying variants, the program explicitly includes elucidating the functional consequences of those variants for the drugs being studied to clarify what the variants do biologically.

How does the opportunity address clinical implications?

A practical emphasis is placed on understanding how genotyping might be used in real-world settings to predict drug response, improve prescribing decisions, reduce adverse events, and advance individualized therapy.

Does this opportunity fund shared resources in addition to individual research projects?

Yes. The announcement emphasizes building shared network resources intended to benefit the entire PGRN community, such as common tools, datasets, methods, and infrastructure.

Why are shared tools and infrastructure important in this program?

The opportunity reinforces that progress depends not only on strong science within individual groups, but also on shared resources that can be used broadly across the network to support coordinated work.

What funding mechanisms were used for this opportunity?

The announcement used NIH cooperative agreements: U01 and U19.

What is significant about using cooperative agreements (U01/U19) instead of standard research grants?

Cooperative agreements typically involve substantial NIH programmatic involvement compared with standard grants. In this program, that aligns with expectations that awardees will coordinate, share, and contribute to collective network activities.

What is the estimated total funding level for this opportunity?

The estimated total funding level was $30,000,000, reflecting support intended to sustain multiple research groups and shared network resources.

What general areas does this opportunity align with?

It is aligned with broad health and biomedical research areas, with CFDA associations spanning biomedical research and training and institute-relevant disease areas such as cardiovascular, lung, blood, cancer, mental health, drug abuse, and reproductive health.

Who was eligible to apply?

Eligibility was broad and included public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), small businesses, and other for-profit organizations that are not small businesses.

Were minority-serving institutions included as eligible applicants?

Yes. The announcement explicitly recognized additional eligible applicant types such as Hispanic-serving Institutions and Historically Black Colleges and Universities (HBCUs).

Was cost-sharing or matching required?

No. There was no cost-sharing or matching requirement.

When was the opportunity posted and when did it close?

The opportunity was posted and created on January 30, 2009. The original and current closing date was June 2, 2009.

Is this funding opportunity still open?

No. The announcement is archived. It had an archive date of July 3, 2009, indicating that the specific opportunity is no longer active.

What does it mean that the announcement is archived?

Based on the dates provided, an archived status indicates the specific funding announcement has passed its closing date and is no longer available for new submissions under that announcement.

What is the key takeaway from this archived opportunity?

The summary captures the intent to expand and strengthen a coordinated pharmacogenomics network that can identify clinically meaningful genetic contributors to drug response, validate them, explain mechanisms, and translate that knowledge into actionable approaches for safer and more effective medication use.